Status:
COMPLETED
Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment
Lead Sponsor:
Massachusetts General Hospital
Conditions:
Breast Cancer Related Lymphedema
Covid19
Eligibility:
FEMALE
18+ years
Brief Summary
This study aims to elicit patient experiences, choices, and side effects associated with the COVID-19 vaccine after breast cancer surgery. Lymph node swelling is a known and common side effect of both...
Detailed Description
* Hypothesis 1: Patients will choose to receive the vaccine on the arm contralateral to axillary lymph node removal, or in the lower extremity if they have had bilateral axillary lymph node removal * ...
Eligibility Criteria
Inclusion
- Female patients who are
- ≥18 years of age and have a
- History of breast cancer For the MGH site, patients must have
- Received some breast cancer treatment at MGH or its affiliates
- Received perometry measurements to measure arm volume at MGH
Exclusion
- None
Key Trial Info
Start Date :
May 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 17 2023
Estimated Enrollment :
714 Patients enrolled
Trial Details
Trial ID
NCT04872738
Start Date
May 7 2021
End Date
March 17 2023
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States, 02114